Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 34

Sort by

Sort Order Select

Journal Articles

TT30, a Novel Regulator of the Complement Alternative Pathway (CAP), Inhibits Hemolysis of Paroxysmal Nocturnal Hemoglobinuria (PNH) Erythrocytes and Prevents Upstream C3 Binding On Their Surface in An in Vitro Model.

Antonio M. Risitano, MD, PhD, V. Michael Holers, Bruno Rotoli

Blood (2009) 114 (22): 158.

https://doi.org/10.1182/blood.V114.22.158.158

Published: 2009

Journal Articles

From Renal Siderosis Due to Perpetual Hemosiderinuria to Possible Liver Overload Due to Extravascular Hemolysis: Changes in Iron Metabolism in Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients On Eculizumab.

Antonio M. Risitano, MD, PhD, Elisa Seneca, Ludovica Marando, Massimo Imbriaco, Ernesto Soscia, Francesca Soscia, Laura Micol Pizzuti, Luca Malcovati, Susanna Fenu, Anna Paola Iori, Rosario Notaro, M.D., Margherita Matarazzo, Bruno Rotoli

Blood (2009) 114 (22): 4031.

https://doi.org/10.1182/blood.V114.22.4031.4031

Published: 2009

Journal Articles

Value of Low Dose IL-2 as Maintenance Following Consolidation Treatment or Autologous Transplantation in Acute Myelogenous Leukemia (AML) Patients Aged 15-60 Years Who Reached CR After High Dose (HD-AraC) Vs Standard Dose (SD-AraC) Cytosine Arabinoside During Induction: Results of the AML-12 Trial of EORTC and GIMEMA Leukemia Groups.

Blood (2009) 114 (22): 791.

https://doi.org/10.1182/blood.V114.22.791.791

Published: 2009

Journal Articles

A Global Registry of Patients with Paroxysmal Nocturnal Hemoglobinuria.

Robert Brodsky, Hubert Schrezenmeier, MD, Petra Muus, MD, PhD, Monica Bessler, MD, PhD, Jeffrey Szer, MBBS, FRACP, Bruno Rotoli, MD, Jaroslaw P. Maciejewski, MD, PhD, Gerard Socie, MD, PhD, A. Urbano-Ispizua, MD, Wendell F. Rosse, MD, Yuzuru Kanakura, MD, PhD, Anders Karnell, Camille Bedrosian, MD, Peter Hillmen, MB, ChB, PhD

Blood (2009) 114 (22): 3007.

https://doi.org/10.1182/blood.V114.22.3007.3007

Published: 2009

Journal Articles

Complement fraction 3 binding on erythrocytes as additional mechanism of disease in paroxysmal nocturnal hemoglobinuria patients treated by eculizumab

Blood (2009) 113 (17): 4094–4100.

https://doi.org/10.1182/blood-2008-11-189944

Published: 2009

Journal Articles

Successful Pregnancy Outcomes in Paroxysmal Nocturnal Hemoglobinuria with Long-Term Eculizumab Treatment

Richard Kelly, MD, Louise Arnold, BSc, MA, Stephen J. Richards, PhD, Anita Hill, MD, Charlotte Bomken, MD, John Hanley, MD, Andrew Loughney, MD, PhD, Gus Khursigara, PhD, Russell P. Rother, PhD, Elizabeth Chalmers, MD, Edward Fitzsimons, MD, Ryotaro Nakamura, MD, Anna Gaya, MD, Bruno Rotoli, MD, Antonio M. Risitano, MD, PhD, Joerg Schubert, MD, Peter Hillmen, MB, PhD

Blood (2008) 112 (11): 4576.

https://doi.org/10.1182/blood.V112.11.4576.4576

Published: 2008

Journal Articles

Subcutaneous Alemtuzumab Is a Safe and Effective Treatment for Global or Single-Lineage Immune-Mediated Marrow Failures: a Survey from the EBMT-WPSAA

Antonio M. Risitano, MD, PhD, Elisa Seneca, Ludovica Marando, Bianca Serio, Carmine Selleri, Giulia Scalia, Luigi Del Vecchio, MD, Annapaola Iori, M.D., Alexander Kulagin, Sebastien Maury, Joerg Halter, Vikas Gupta, MD, MRCP, MRCPath, Andrea Bacigalupo, MD, Gerard Socié, Andre Tichelli, Judith Marsh, Hubert Schrezenmeier, Jakob R. Passweg, MD, MS, Bruno Rotoli

Blood (2008) 112 (11): 1042.

https://doi.org/10.1182/blood.V112.11.1042.1042

Published: 2008

Journal Articles

High Dose (HD-AraC) Vs Standard Dose Cytosine Arabinoside (SDAraC) during Induction and Value of IL-2 during Maintenance in Acute Myelogenous Leukemia (AML): Impact of AraC Dose on Complete Remission Rate and Toxicity (Results on the first 1700 randomized patients of the AML-12 trial of EORTC and GIMEMA Leukemia Groups)

Blood (2008) 112 (11): 134.

https://doi.org/10.1182/blood.V112.11.134.134

Published: 2008

Journal Articles

Role of the Urokinase Receptor (uPAR) in the Cross-Talk of Hematopoietic Stem Cells with the Bone Marrow Microenvironment

Nunzia Montuori, PhD, Patrizia Ricci, Bianca Serio, Valeria Visconte, PhD, Claudio La Penna, Ada Pesapane, Antonio M. Risitano, MD, PhD, Bruno Rotoli, Guido Rossi, Pia Ragno, PhD, Carmine Selleri

Blood (2008) 112 (11): 324.

https://doi.org/10.1182/blood.V112.11.324.324

Published: 2008

Journal Articles

C3-Mediated Extravascular Hemolysis as Additional Mechanism of Disease in Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients Treated by the Complent Inhibitor Eculizumab

Blood (2008) 112 (11): 485.

https://doi.org/10.1182/blood.V112.11.485.485

Published: 2008

Journal Articles

CD200: a New Target for Immunotherapy in Hematologic Malignancies.

Lorenzo Brunetti, Giovanna Abate, Marisa Gorrese, Maddalena Raia, Caterina Pascariello, Giulia Scalia, Bruno Rotoli, Luigi Del Vecchio

Blood (2008) 112 (11): 1598.

https://doi.org/10.1182/blood.V112.11.1598.1598

Published: 2008

Journal Articles

Hemoglobin normalization after splenectomy in a paroxysmal nocturnal hemoglobinuria patient treated by eculizumab

Antonio M. Risitano, Ludovica Marando, Elisa Seneca, Bruno Rotoli

Blood (2008) 112 (2): 449–451.

https://doi.org/10.1182/blood-2008-04-151613

Published: 2008

Journal Articles

Subcutaneous Alemtuzumab Is Safe and Effective for Treatment of Global or Single-Lineage Immune-Mediated Marrow Failure: A Pilot Study.

Antonio M. Risitano, MD, PhD, Carmine Selleri, MD, Bianca Serio, MD, Ludovica Marando, Andrea Camera, MD, Lucio Catalano, MD, Giulia Scalia, PhD, Luigi Del Vecchio, MD, Bruno Rotoli, MD

Blood (2007) 110 (11): 1692.

https://doi.org/10.1182/blood.V110.11.1692.1692

Published: 2007

Journal Articles

GATA1 Is Over-Expressed in Essential Thrombocytemia

Ciro R. Rinaldi, MD, Donglan Li, MD, Rosanna Ciancia, MD, Marco Picardi, MD, Paola Rinaldi, Vincenzo Martinelli, MD, Giuseppina Nucifora, PhD, Fabrizio Pane, MD, Bruno Rotoli, MD

Blood (2007) 110 (11): 1534.

https://doi.org/10.1182/blood.V110.11.1534.1534

Published: 2007

Journal Articles

HLA B1402, Cw0802 Haplotype and DRB1*1501 Allele Are Significantly Increased in Italian Paroxysmal Nocturnal Hemoglobinuria Affected Patients.

Fiorella Alfinito, Elena Cosentini, Rosa Camerlengo, Giuseppe Terrazzano, Michela Sica, Antonio Risitano, Stefania Costagliola, Roberta Della Pepa, Carmela Palladino, Lucio Luzzatto, Bruno Rotoli, Rosario Notaro, Giuseppina Ruggiero

Blood (2007) 110 (11): 4035.

https://doi.org/10.1182/blood.V110.11.4035.4035

Published: 2007

Journal Articles

Liposomal Cytarabine (Depocyte®) for the Treatment of Meningeal or CNS Disease in Acute Leukemias (AL) and Non-Hodgkin Lymphomas (NHL): A Single Centre Experience.

Andrea Camera, MD, Giuseppe Cerciello, MD, Fabiana Perna, MD, Ciro R. Rinaldi, MD, Elefanti Michele, Silvia Ferrari, Bruno Rotoli, MD

Blood (2006) 108 (11): 4540.

https://doi.org/10.1182/blood.V108.11.4540.4540

Published: 2006

Journal Articles

Subcutaneous Alemtuzumab as Treatment Option for Patients with Severe Aplastic Anemia or Lineage-Restricted Aplasia.

Antonio M. Risitano, MD, PhD, Carmine Selleri, MD, Andrea Camera, MD, Giovanni Gallotta, MD, Fabiana Perna, MD, Giampaolo Copeta, MD, Bruno Rotoli, MD

Blood (2006) 108 (11): 3754.

https://doi.org/10.1182/blood.V108.11.3754.3754

Published: 2006

Journal Articles

Safety and Efficacy of the Terminal Complement Inhibitor Eculizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria: Interim Shepherd Phase III Clinical Study.

Neal S. Young, MD, Elisabetta Antonioli, MD, Bruno Rotoli, MD, Hubert Schrezenmeier, MD, Jörg Schubert, MD, Alvaro Urbano-Ispizua, MD, Luke Coyle, MD, Carlos de Castro, MD, Chieh-Lin Fu, MD, Jaroslaw P. Maciejewski, MD, PhD, Christopher F. Mojcik, MD, PhD, Russell P. Rother, PhD, Peter Hillmen, MB PhD

Blood (2006) 108 (11): 971.

https://doi.org/10.1182/blood.V108.11.971.971

Published: 2006

Journal Articles

Blockade of Intravascular Hemolysis in PNH with the Terminal Complement Inhibitor Eculizumab Unmasks Low-Level Hemolysis Potentially Occurring through C3 Opsonization.

Anita Hill, MD, Russell P. Rother, PhD, Antonio M. Risitano, PhD, Duncan S. Cole, PhD, Matthew J. Cullen, MSc, Stephen J. Richards, PhD, Carmine Selleri, MD, Patrizia Ricci, BSc, Bruno Rotoli, MD, Lucio Luzzatto, PhD, Peter Hillmen, PhD

Blood (2006) 108 (11): 972.

https://doi.org/10.1182/blood.V108.11.972.972

Published: 2006

Journal Articles

Chromosome Abnormalities in Multiple Myeloma Patients: Impact on Prognosis and Survival.

Lulgia Luciano, MD, Rosamaria De Luca, PhD, Anna Guerriero, PhD, Lucio Catalano, MD, Ferdinando Frigeri, MD, Fara Petruzziello, MD, Fabrizio Pane, MD, Bruno Rotoli, MD

Blood (2006) 108 (11): 5054.

https://doi.org/10.1182/blood.V108.11.5054.5054

Published: 2006

NARROW

TT30, a Novel Regulator of the Complement Alternative Pathway (CAP), Inhibits Hemolysis of Paroxysmal Nocturnal Hemoglobinuria (PNH) Erythrocytes and Prevents Upstream C3 Binding On Their Surface in An in Vitro Model.

From Renal Siderosis Due to Perpetual Hemosiderinuria to Possible Liver Overload Due to Extravascular Hemolysis: Changes in Iron Metabolism in Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients On Eculizumab.

A Global Registry of Patients with Paroxysmal Nocturnal Hemoglobinuria.

Complement fraction 3 binding on erythrocytes as additional mechanism of disease in paroxysmal nocturnal hemoglobinuria patients treated by eculizumab

Successful Pregnancy Outcomes in Paroxysmal Nocturnal Hemoglobinuria with Long-Term Eculizumab Treatment

Subcutaneous Alemtuzumab Is a Safe and Effective Treatment for Global or Single-Lineage Immune-Mediated Marrow Failures: a Survey from the EBMT-WPSAA

Role of the Urokinase Receptor (uPAR) in the Cross-Talk of Hematopoietic Stem Cells with the Bone Marrow Microenvironment

C3-Mediated Extravascular Hemolysis as Additional Mechanism of Disease in Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients Treated by the Complent Inhibitor Eculizumab

CD200: a New Target for Immunotherapy in Hematologic Malignancies.

Hemoglobin normalization after splenectomy in a paroxysmal nocturnal hemoglobinuria patient treated by eculizumab

Subcutaneous Alemtuzumab Is Safe and Effective for Treatment of Global or Single-Lineage Immune-Mediated Marrow Failure: A Pilot Study.

GATA1 Is Over-Expressed in Essential Thrombocytemia

HLA B1402, Cw0802 Haplotype and DRB1*1501 Allele Are Significantly Increased in Italian Paroxysmal Nocturnal Hemoglobinuria Affected Patients.

Liposomal Cytarabine (Depocyte®) for the Treatment of Meningeal or CNS Disease in Acute Leukemias (AL) and Non-Hodgkin Lymphomas (NHL): A Single Centre Experience.

Subcutaneous Alemtuzumab as Treatment Option for Patients with Severe Aplastic Anemia or Lineage-Restricted Aplasia.

Safety and Efficacy of the Terminal Complement Inhibitor Eculizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria: Interim Shepherd Phase III Clinical Study.

Blockade of Intravascular Hemolysis in PNH with the Terminal Complement Inhibitor Eculizumab Unmasks Low-Level Hemolysis Potentially Occurring through C3 Opsonization.

Chromosome Abnormalities in Multiple Myeloma Patients: Impact on Prognosis and Survival.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only